Compare BNL & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNL | TLX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.3B |
| IPO Year | 2020 | N/A |
| Metric | BNL | TLX |
|---|---|---|
| Price | $17.50 | $8.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $19.86 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 1.9M | 169.8K |
| Earning Date | 10-29-2025 | 01-15-2026 |
| Dividend Yield | ★ 6.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.47 | 0.04 |
| Revenue | $447,973,000.00 | ★ $664,225,558.00 |
| Revenue This Year | $5.83 | N/A |
| Revenue Next Year | $7.20 | N/A |
| P/E Ratio | ★ $37.30 | $249.18 |
| Revenue Growth | 5.49 | ★ 55.35 |
| 52 Week Low | $13.96 | $7.72 |
| 52 Week High | $18.87 | $30.36 |
| Indicator | BNL | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 33.92 |
| Support Level | $17.25 | $7.72 |
| Resistance Level | $17.91 | $8.22 |
| Average True Range (ATR) | 0.27 | 0.25 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 38.30 | 13.42 |
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.